Thought provoking article. TLDR: we are generating novel ideas at the same pace, but the downstream barriers to getting them translated are getting worse. In particular, more innovative players are increasingly disadvantaged in markets. I’m still digesting this, especially thinking about biotech and the enormous downstream barrier that clinical development places on new ideas. My early impression (not a novel one), even before this article, was that the real problem isn’t as idea generation but downstream inefficiency in clinical development, which I've extensively written about. Regulatory constraints hit small companies and academic trials much harder, and that feels more corrosive to innovation than big pharma being slowed down, because it systematically disadvantages the most exploratory players.

Came across this article in @stuartbuck1 's newsletter

@stuartbuck1 @StefanFSchubert you should cover it in your news story